Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 1
2015 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Stern A, et al. Cochrane Database Syst Rev. 2014 Oct 1;2014(10):CD005590. doi: 10.1002/14651858.CD005590.pub3. Cochrane Database Syst Rev. 2014. PMID: 25269391 Free PMC article. Review.
BACKGROUND: Pneumocystis pneumonia (PCP) is a disease affecting immunocompromised patients. ...We contacted authors of the included trials to obtain missing data. The primary outcome was documented PCP infections. Risk ratios (RR) with 95% confidence interval …
BACKGROUND: Pneumocystis pneumonia (PCP) is a disease affecting immunocompromised patients. ...We contacted authors of the inc …
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/L and virologic suppression: a systematic review.
Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Costiniuk CT, et al. PLoS One. 2011;6(12):e28570. doi: 10.1371/journal.pone.0028570. Epub 2011 Dec 16. PLoS One. 2011. PMID: 22194853 Free PMC article. Review.
BACKGROUND: HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophylaxis discontinuation, but suppression of plasma viremia with antiretroviral therapy may allow for discontinuation of PCP prophylaxis even w …
BACKGROUND: HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophy …
Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, Rjeily MB, Butler-Laporte G, McDonald EG, Lee TC. Prosty C, et al. Clin Microbiol Infect. 2024 Apr 6:S1198-743X(24)00168-X. doi: 10.1016/j.cmi.2024.03.037. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38583518 Free article. Review.
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PWH), particularly among new and untreated cases. ...Data on PCP incidence, all-cause mortality, and discontinuation due to toxicity were pool …
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PW …
Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under.
Onakpoya IJ, Hayward G, Heneghan CJ. Onakpoya IJ, et al. Cochrane Database Syst Rev. 2015 Sep 26;2015(9):CD011530. doi: 10.1002/14651858.CD011530.pub2. Cochrane Database Syst Rev. 2015. PMID: 26408070 Free PMC article. Review.
OBJECTIVES: To assess the effectiveness and safety of antibiotic prophylaxis in the prevention of bacterial LRTIs in high-risk children aged 12 years and under. ...Our primary outcome was the incidence of bacterial lower respiratory infections. ...
OBJECTIVES: To assess the effectiveness and safety of antibiotic prophylaxis in the prevention of bacterial LRTIs in high-risk childr …